AstraZeneca PLC vs Catalyst Pharmaceuticals, Inc.: SG&A Expense Trends

SG&A Expense Trends: AstraZeneca PLC vs Catalyst Pharmaceuticals, Inc.

In the ever-evolving pharmaceutical industry, understanding financial trends is crucial. Over the past decade, AstraZeneca PLC and Catalyst Pharmaceuticals, Inc. have shown contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. AstraZeneca, a global leader, has seen its SG&A expenses grow by approximately 35% from 2014 to 2023, peaking in 2022. This reflects its expansive global operations and strategic investments in R&D and marketing. In contrast, Catalyst Pharmaceuticals, a smaller player, experienced a staggering 2,887% increase in SG&A expenses over the same period, highlighting its aggressive growth strategy and market penetration efforts. The year 2023 marked a significant leap for Catalyst, with expenses more than doubling from the previous year, indicating a pivotal expansion phase. These trends underscore the diverse strategies employed by pharmaceutical companies to navigate competitive landscapes and drive growth.